Viskase 

$5.50
0
-$0.30-5.17% Thursday 13:30

Statistics

Day High
6.6
Day Low
6.5
52W High
34.81
52W Low
5
Volume
1,000
Avg. Volume
915
Mkt Cap
78.83M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Sep 19
$0.12
Mar 19
$6.00
Sep 17
$15.00
Dec 16
$15.00
Dec 15
$25.00
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENZND. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap158.77B
Gilead Sciences is a biopharmaceutical company that competes in the development of drugs for infectious diseases, a market Enzon Pharmaceuticals also targets.
AMGEN
AMGN
Mkt Cap193.39B
Amgen is a biotech firm focusing on novel therapeutics, including treatments for serious illnesses, overlapping with Enzon's therapeutic areas.
Bristol-Myers Squibb
BMY
Mkt Cap117.46B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, similar to Enzon's mission.
Pfizer
PFE
Mkt Cap138.44B
Pfizer is a global pharmaceutical company with a broad range of drugs and vaccines, competing across several of the same therapeutic areas as Enzon.
Merck
MRK
Mkt Cap317.77B
Merck operates in the pharmaceutical sector, focusing on drugs for conditions that Enzon Pharmaceuticals also aims to treat, making them direct competitors.
Abbvie
ABBV
Mkt Cap447.62B
AbbVie is a research-based biopharmaceutical company with a significant focus on developing treatments for serious diseases, competing with Enzon in drug development.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.35B
Regeneron Pharmaceuticals specializes in the invention of medicines for serious medical conditions, directly competing with Enzon in the biopharmaceutical field.
Biogen
BIIB
Mkt Cap31.89B
Biogen is a biotechnology company that develops therapies for neurological and neurodegenerative diseases, competing with Enzon in the biopharmaceutical market.
Vertex Pharmaceuticals
VRTX
Mkt Cap124.7B
Vertex Pharmaceuticals is known for creating new possibilities in medicine to cure diseases and improve people's lives, competing with Enzon in drug innovation.
Novartis
NVS
Mkt Cap296.54B
Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide, including areas where Enzon operates.

About

Enzon Pharmaceuticals, Inc., along with its various subsidiaries, primarily focuses on the commercialization of pharmaceutical products. PegIntron is a key drug within its actively marketed portfolio. The company also maintains a specific marketing agreement for the medication Vicineum. Established in 1981, Enzon Pharmaceuticals is headquartered in Cranford, New Jersey.
Show more...
CEO
Mr. Maurice J. Ryan
Employees
1
Country
United States

Listings

0 Comments

Share your thoughts

FAQ

What is Viskase stock price today?
The current price of ENZND is $5.50 USD — it has decreased by -5.17% in the past 24 hours. Watch Viskase stock price performance more closely on the chart.
What is Viskase stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Viskase stocks are traded under the ticker ENZND.
What is Viskase market cap?
Today Viskase has the market capitalization of 78.83M
Does Viskase pay dividends?
Yes, ENZND dividends are paid annual. The last dividend per share was 0.12 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Viskase have?
As of July 02, 2026, the company has 1 employees.
In which sector is Viskase located?
Viskase operates in the Health & Wellness sector.
When did Viskase complete a stock split?
The last stock split for Viskase was on March 25, 2026 with a ratio of 1:100.
Where is Viskase headquartered?
Viskase is headquartered in Lombard, United States.